机译:Patiromer for the management of hyperkalaemia in patients receiving renin–angiotensin–aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial
Department of Medicine,University of Mississippi;
Department of Cardiology (CVK);
and Berlin Institute of Health Center for Regenerative Therapies;
Department of Internal Medicine,Dow University of Health SciencesUniversity of WarwickVifor PharmaNational and Kapodistrian University of Athens, School of Medicine, Athens University HospitalUniversity Medical Center G?ttingenDepartment of Cardiovascular Disease,Saint Luke's Mid America Heart Institute and University ofDepartment of Medicine, Unit of Cardiology,Karolinska InstituteDepartment of Cardiology,University and Civil HospitalCentral Michigan UniversitySanta Maria University Hospital, CAML, CCUL, Faculdade de Medicina da Universidade de LisboaCentre d'Investigation Clinique Plurithématique Pierre Drouin ‐ INSERM CHU de NancyDepartment of Cardiology,University Medical Center GroningenDivision of Nephrology, Department of Medicine,University of Maryland School of MedicineDivision of Cardiology,University of Michigan;
Heart failure; Potassium; Hyperkalaemia; Patiromer; Renin–angiotensin–aldosterone system inhibitors; Mineralocorticoid receptor antagonists; Adherence; Trial design;